Bauknecht T, Runge M, Schwall M, Pfleiderer A
Universitäts-Frauenklinik, Freiburg, Federal Republic of Germany.
Gynecol Oncol. 1988 Feb;29(2):147-57. doi: 10.1016/0090-8258(88)90209-0.
Ninety-eight different malignant adnexal tumors were analyzed for the presence of epidermal growth factor (EGF)-specific binding sites and binding parameters were calculated by Scatchard plot analysis [G. Scatchard, Ann. N.Y. Acad. Sci. 51, 660-672 (1949)]. Thirty-four biopsies were EGF receptor (EGF-R) positive with dissociation constants (KD) of 0.5-12 X 10(-9) M and binding capacities (Bmax) of 2-250 fmol/mg. One tumor had a KD of 60 X 10(-9) M and a Bmax of 1660 fmol/mg. The correlation of EGF-R status with clinical parameters showed no significant differences in primary, metastatic, or recurrent tumors, histological subtype, tumor differentiation, and tumor residual after primary surgery. As an inverse correlation, EGF-R-positive tumors are 39% and EGF-R-negative tumors 60% progesterone receptor positive. A response to chemotherapy was noticed in 50% of EGF-R-positive ovarian carcinomas with a mean survival time of patients of 28 months. The response rate of EGF-R negative ovarian carcinomas was 12% with a mean survival time of 16 months. Regarding the treatment schedule the major differences were noticed in the cis-platinum plus cyclophosphamide treatment group. These results suggest that the biology of ovarian carcinomas is influenced by growth factors and their receptors, which can be used as prognostic factors.
对98种不同的恶性附属器肿瘤进行了分析,以检测表皮生长因子(EGF)特异性结合位点的存在情况,并通过Scatchard图分析计算结合参数[G. Scatchard,《纽约科学院学报》51,660 - 672(1949年)]。34份活检标本的表皮生长因子受体(EGF-R)呈阳性,解离常数(KD)为0.5 - 12×10⁻⁹ M,结合容量(Bmax)为2 - 250 fmol/mg。有一个肿瘤的KD为60×10⁻⁹ M,Bmax为1660 fmol/mg。EGF-R状态与临床参数的相关性显示,在原发性、转移性或复发性肿瘤、组织学亚型、肿瘤分化程度以及初次手术后的肿瘤残留情况方面均无显著差异。呈负相关的是,EGF-R阳性肿瘤中39%孕激素受体呈阳性,EGF-R阴性肿瘤中60%孕激素受体呈阳性。在50%的EGF-R阳性卵巢癌中观察到对化疗有反应,患者的平均生存时间为28个月。EGF-R阴性卵巢癌的反应率为12%,平均生存时间为16个月。关于治疗方案,在顺铂加环磷酰胺治疗组中观察到了主要差异。这些结果表明,卵巢癌的生物学特性受生长因子及其受体的影响,它们可作为预后因素。